Research finds that GLP-1 receptor agonists significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetes patients compared to insulins, but show varied results against metformin.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
Ivonescimab — a novel first-in-class PD-1/VEGF bispecific antibody — led to clinically meaningful improvement in progression-free survival (PFS) compared with pembrolizumab (Keytruda) as first-line therapy